Key result
Myocardial extracellular volume fraction determined by cardiac computed tomography was significantly higher in patients with cancer therapeutics-related cardiac dysfunction compared to controls.
Why the study?
Cardiotoxicity in the late phase following anthracycline administration remains to be defined.
Does cardiac computed tomography (CCT)-derived extracellular volume fraction effectively evaluate cancer therapeutics-related cardiac dysfunction (CTRCD) compared to echocardiography in patients who received anthracycline treatment?
Observational (n=44)
Does cardiac computed tomography (CCT)-derived extracellular volume fraction effectively evaluate cancer therapeutics-related cardiac dysfunction (CTRCD) compared to echocardiography in patients who received anthracycline treatment?
Answers are grounded in this paper and cite their sources.
Cardiac computed tomography-derived extracellular volume fraction is a comparable tool to echocardiography for evaluating late anthracycline-induced cardiotoxicity.
Cardiotoxicity in the late phase after anthracycline drugs administration remains to be defined. Of the 44 patients who received anthracycline treatment, 7 were found to have cancer therapeutics-related cardiac dysfunction (CTRCD). The global longitudinal strain determined by echocardiography and myocardial extracellular volume fraction (ECV) determined by cardiac computed tomography (CCT) of the CTRCD(+) group were significantly higher than those of the control group and CTRCD(-) group, whereas there were no significant differences between the control and CTRCD(-) groups. Our findings indicated that CCT may be a tool comparable to echocardiography, indicating the effective evaluation of CTRCD by CCT.
No takes yet. Share an insight, caveat, or question.
Egashira et al. (2021) conducted an observational in Anthracycline-induced cardiotoxicity (n=44). Cancer therapeutics-related cardiac dysfunction (CTRCD) vs. CTRCD(-) patients and control group was evaluated on Global longitudinal strain by echocardiography and myocardial extracellular volume fraction (ECV) by cardiac computed tomography. Myocardial extracellular volume fraction determined by cardiac computed tomography was significantly higher in patients with cancer therapeutics-related cardiac dysfunction compared to controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: